{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:04:57Z","timestamp":1791295497475,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Delayed graft function (DGF) is associated with adverse long-term outcomes after deceased-donor kidney (DDK) transplantation. Ischemia-reperfusion injury plays a crucial role in the development of DGF. On the basis of promising animal data, this study evaluated any potential benefits of erythropoietin-alfa (EPO-\u03b1) given intra-arterially at the time of reperfusion of renal allograft on the degree of allograft function, as well as tubular cell injury measured by urinary biomarkers in the early post-transplant period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>A prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the influence of EPO-\u03b1 administered intraoperatively on the outcomes of DDK transplantations performed at the study center between March 2007 and July 2009.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-two patients were randomly assigned to EPO-\u03b1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =36) or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =36). The incidences of DGF, slow graft function, and immediate graft function did not significantly differ between the treatment and control groups (41.7% versus 47.2%, 25.0% versus 36.1%, and 33.3% versus 16.7%, respectively;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.24). The groups had similar levels of urinary biomarkers, including neutrophil gelatinase-associated lipocalin and IL-18 at multiple times points soon after transplantation; urinary output during the first 3 postoperative days; 1-month renal function; and BP readings, hemoglobin, and adverse effects during the first month.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study did not show any clinically demonstrable beneficial effects of high-dose EPO-\u03b1 given intra-arterially during the early reperfusion phase in DDK transplant recipients in terms of reducing the incidence of DGF or improving short-term allograft function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.01360212","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T20:13:56Z","timestamp":1341000836000},"page":"1498-1506","source":"Crossref","is-referenced-by-count":48,"title":["Effect of High-Dose Erythropoietin on Graft Function after Kidney Transplantation"],"prefix":"10.2215","volume":"7","author":[{"given":"Kalathil K.","family":"Sureshkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha M.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Y.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc L.","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20230811","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ndt\/gfn667","article-title":"Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis.","volume":"24","author":"Yarlagadda","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R2-17-20230811","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1681\/ASN.2009040412","article-title":"Delayed graft function and the risk for death with a functioning graft.","volume":"21","author":"Tapiawala","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R3-17-20230811","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/00007890-199704150-00011","article-title":"Delayed graft function: Risk factors and implications for renal allograft survival.","volume":"63","author":"Ojo","year":"1997","journal-title":"Transplantation"},{"key":"R4-17-20230811","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2011.03754.x","article-title":"Delayed graft function in the kidney transplant.","volume":"11","author":"Siedlecki","year":"2011","journal-title":"Am J Transplant"},{"key":"R5-17-20230811","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/01.ASN.0000135059.67385.5D","article-title":"Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.","volume":"15","author":"Sharples","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R6-17-20230811","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1523-1755.2004.00400.x","article-title":"Cytoprotection by darbepoetin\/epoetin alfa in pig tubular and mouse mesangial cells.","volume":"65","author":"Fishbane","year":"2004","journal-title":"Kidney Int"},{"key":"R7-17-20230811","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/ndt\/gfg547","article-title":"Erythropoietin protects against ischaemic acute renal injury.","volume":"19","author":"Vesey","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R8-17-20230811","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ndt\/16.5.932","article-title":"Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat.","volume":"16","author":"Bagnis","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R9-17-20230811","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1523-1755.2004.00847.x","article-title":"Pretreatment with EPO reduces the injury and dysfunction caused by ischemia\/reperfusion in the mouse kidney in vivo.","volume":"66","author":"Patel","year":"2004","journal-title":"Kidney Int"},{"key":"R10-17-20230811","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/sj.ki.5000356","article-title":"Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure.","volume":"69","author":"Johnson","year":"2006","journal-title":"Kidney Int"},{"key":"R11-17-20230811","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/ndt\/gfi177","article-title":"Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic\/reperfusion model.","volume":"21","author":"Spandou","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R12-17-20230811","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-17-20230811","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.051606598","article-title":"Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress.","volume":"98","author":"Sir\u00e9n","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-17-20230811","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1161\/01.CIR.0000127954.98131.23","article-title":"Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia\/reperfusion injury.","volume":"109","author":"Cai","year":"2004","journal-title":"Circulation"},{"key":"R15-17-20230811","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1172\/JCI18200","article-title":"A novel protective effect of erythropoietin in the infarcted heart.","volume":"112","author":"Parsa","year":"2003","journal-title":"J Clin Invest"},{"key":"R16-17-20230811","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1515\/CCLM.2011.664","article-title":"New biomarkers for acute renal injury.","volume":"49","author":"Soni","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"R17-17-20230811","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1681\/ASN.2010121302","article-title":"Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery.","volume":"22","author":"Parikh","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R18-17-20230811","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1600-6143.2006.01352.x","article-title":"Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation.","volume":"6","author":"Parikh","year":"2006","journal-title":"Am J Transplant"},{"key":"R19-17-20230811","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.2009030264","article-title":"IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation.","volume":"21","author":"Hall","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R20-17-20230811","first-page":"63","article-title":"Acute kidney injury biomarkers\u2014needs, present status, and future promise.","volume":"5","author":"Zhou","year":"2006","journal-title":"NephSAP"},{"key":"R21-17-20230811","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(05)74811-X","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.","volume":"365","author":"Mishra","year":"2005","journal-title":"Lancet"},{"key":"R22-17-20230811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.ajkd.2003.10.040","article-title":"Urinary interleukin-18 is a marker of human acute tubular necrosis.","volume":"43","author":"Parikh","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R24-17-20230811","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1523-1755.1999.055003808.x","article-title":"Human, rat, and mouse kidney cells express functional erythropoietin receptors.","volume":"55","author":"Westenfelder","year":"1999","journal-title":"Kidney Int"},{"key":"R25-17-20230811","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1161\/01.CIR.0000039103.58920.1F","article-title":"Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases.","volume":"106","author":"Chong","year":"2002","journal-title":"Circulation"},{"key":"R26-17-20230811","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway.","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"R27-17-20230811","doi-asserted-by":"crossref","first-page":"F1354","DOI":"10.1152\/ajprenal.00131.2008","article-title":"Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury.","volume":"294","author":"Salahudeen","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"R28-17-20230811","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/TP.0b013e3182241106","article-title":"Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia\/reperfusion in rats.","volume":"92","author":"Cassis","year":"2011","journal-title":"Transplantation"},{"key":"R29-17-20230811","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1073\/pnas.95.8.4635","article-title":"In vivo evidence that erythropoietin protects neurons from ischemic damage.","volume":"95","author":"Sakanaka","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-17-20230811","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0014-2999(00)00466-0","article-title":"Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation.","volume":"401","author":"Calapai","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"R31-17-20230811","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/35088074","article-title":"Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades.","volume":"412","author":"Digicaylioglu","year":"2001","journal-title":"Nature"},{"key":"R32-17-20230811","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1161\/STROKEAHA.109.564872","article-title":"Recombinant human erythropoietin in the treatment of acute ischemic stroke.","volume":"40","author":"Ehrenreich","year":"2009","journal-title":"Stroke"},{"key":"R33-17-20230811","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.amjcard.2009.05.050","article-title":"Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction.","volume":"104","author":"Binbrek","year":"2009","journal-title":"Am J Cardiol"},{"key":"R34-17-20230811","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2011.592","article-title":"Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized controlled trial.","volume":"305","author":"Najjar","year":"2011","journal-title":"JAMA"},{"key":"R35-17-20230811","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ki.2011.349","article-title":"High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation.","volume":"81","author":"Hafer","year":"2012","journal-title":"Kidney Int"},{"key":"R37-17-20230811","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ki.2010.25","article-title":"Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).","volume":"77","author":"Endre","year":"2010","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201209000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:19Z","timestamp":1786369339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201209000-00017"}},"subtitle":["A Randomized, Double-Blind Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01360212","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950013.793455216","asserted-by":"object"}]},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}